Abbott Laboratories Analyst Is Bullish About MedTech, Non-MedTech Growth
Abbott Laboratories Analyst Is Bullish About MedTech, Non-MedTech Growth
Abbott Laboratories's (NYSE:ABT) MedTech portfolio is growing at a CAGR (compounded annual growing rate) of 11%-13%.
雅培实验室（NYSE:ABT）的医疗科技投资组合以每年11%-13%的复合年增长率增长。
The company's non-MedTech operations are expanding by low-to-mid single-digit percentages, according to Oppenheimer.
根据Oppenheimer的说法，该公司的非医疗科技业务正以低至中个位数的百分比扩张。
Analyst Suraj Kalia initiated coverage of Abbott Laboratories with an Outperform rating and price target of $130.
分析师Suraj Kalia开始覆盖雅培实验室，并给出了$130的表现评级和价格目标。
The Abbott Laboratories Thesis: The company's MedTech portfolio currently contributes around 45% of total sales of about $42 billion, Kalia said in the initiation note.
雅培实验室的论点：卡利亚在启动笔记中称，公司的医疗科技投资组合目前约占总销售额约420亿美元的45%。
Check out other analyst stock ratings.
查看其他分析师的股票评级。
Abbott's product pipeline boosts confidence in the company's long-term growth, the analyst stated.
雅培的产品管道增强了对公司长期增长的信恳智能，该分析师称。
While its various offerings provide "structural advantages for product bundling," the company has also made disciplined MedTech acquisitions, he added.
尽管其各种产品提供了"产品捆绑的结构优势"，但该公司还进行了纪律严明的医疗科技收购，他补充道。
On the non-MedTech side, Nutrition and Diagnostics sales comps will ease over the next few years, driving revenue growth with margin expansion of 30 to 50 basis points per year in fiscal 2026 and beyond, Kalia further wrote.
在非医疗科技方面，营养和诊断销售的对比将在未来几年内放缓，在2026财年及以后，Kalia进一步写道，将带动收入增长和每年30至50个基点的利润率扩张。
Price Action: Shares of Abbott Laboratories had risen by 0.7% to $114.17 at the time of publication on Tuesday.
股价走势：在周二发布时，雅培股票上涨了0.7%，至114.17美元。
Read More:
阅读更多：
- Expanding Continuous Glucose Monitoring Options: How Glucotrack Is Helping Usher In The Next Generation Of Diabetes Care Technology
- 拓展连续血糖监测期权：Glucotrack如何帮助迎接糖尿病护理科技的下一代
Image: Shutterstock
图片：shutterstock
